A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Bayer; Bayer HealthCare
- 21 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2021.
- 21 Sep 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2021.
- 29 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2018 as reported by ClinicalTrials.gov record.